The estimated Net Worth of Venture Associates Iii Ltd ... is at least 25.3 百万$ dollars as of 24 June 2019. Venture Ltd owns over 197,000 units of Minerva Neurosciences Inc stock worth over 10,410,835$ and over the last 10 years Venture sold NERV stock worth over 14,839,510$.
Venture has made over 12 trades of the Minerva Neurosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Venture sold 197,000 units of NERV stock worth 1,183,970$ on 24 June 2019.
The largest trade Venture's ever made was buying 1,620,833 units of Minerva Neurosciences Inc stock on 7 July 2014 worth over 9,724,998$. On average, Venture trades about 278,091 units every 139 days since 2014. As of 24 June 2019 Venture still owns at least 3,899,189 units of Minerva Neurosciences Inc stock.
You can see the complete history of Venture Ltd stock trades at the bottom of the page.
Over the last 10 years, insiders at Minerva Neurosciences Inc have traded over 49,043,620$ worth of Minerva Neurosciences Inc stock and bought 8,182,692 units worth 47,876,311$ . The most active insiders traders include & Johnson Johnson & Johnson...、Venture Associates Iii Ltd ...、Capital Iii Llc Care Capita.... On average, Minerva Neurosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of 556,476$. The most recent stock trade was executed by Remy Luthringer on 28 April 2023, trading 27,394 units of NERV stock currently worth 105,193$.
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
Minerva Neurosciences Inc executives and other stock owners filed with the SEC include: